In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

B7-DC, one of the recently described B7 family members, has the capacity to inhibit T cell responses via engagement of the immunoreceptor tyrosine-based inhibitory motif–containing inhibitory PD-1 receptor as well as enhance responses via an as yet unidentified costimulatory receptor. B7-DC is highly homologous to a coinhibitory B7 family member, B7-H1, which also binds PD-1. It is currently unclear which B7-DC function—costimulation or inhibition—predominates in vivo. To study in vivo functions of B7-DC, we evaluated immune responses in B7-DC knockout (KO) mice. Although not eliminated, interferon-γ (IFN-γ) production by CD4 T cells and IFN-γ–dependent humoral responses were reduced in B7-DC KO mice relative to wild type mice. Antigen-specific CD8 T cell responses and cytotoxic T lymphocyte (CTL) activity were also diminished in B7-DC KO mice. Hepatic tumors grew more quickly in B7-DC KO mice, associated with a decrease in intrahepatic tumor-specific CD8 T cells. These results highlight the contrasting in vivo roles of B7-DC and B7-H1 and indicate that B7-DC functions as a tuning molecule, selectively augmenting T helper 1 and CTL responses.

• Publication year

  2005

• Venue

  Journal of Experimental Medicine

• Publication date

  2005-05-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20050072PMID 15897272PMCID 2212923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of Foxp3 regulatory gene expression with graft-versus-host disease.

  2004cited by this paper
• B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• A role for the immunological synapse in lineage commitment of CD4 lymphocytes

  2004cited by this paper
• B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

  2004cited by this paper
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

  2003cited by this paper
• B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism

  2003cited by this paper
• A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer.

  2003cited by this paper
• Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions

  2003cited by this paper
• Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor

  2003cited by this paper
• BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

  2003cited by this paper
• Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis

  2003cited by this paper
• Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction

  2003cited by this paper
• Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

  2003cited by this paper
• Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells 1

  2003cited by this paper
• New regulatory co-receptors: inducible co-stimulator and PD-1.

  2002cited by this paper
• PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2

  2002cited by this paper
• B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis1

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• Estimation of the lowest triplet π,π* energy level of 1,4-tetracenequinone by use of triplet energy transfer in solution

  2002cited by this paper
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

  2002cited by this paper
• Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells

  2002cited by this paper
• Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

  2002cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen

  2001cited by this paper
• B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• A novel transcription factor, T-bet, directs Th1 lineage commitment.

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Costimulatory regulation of T cell function.

  1999cited by this paper
• CD8(+) T cell-mediated spontaneous diabetes in neonatal mice.

  1996cited by this paper
• Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.

  1993cited by this paper

• Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling

  2025cites this paper
• Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities

  2024cites this paper
• Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment

  2023cites this paper
• Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression.

  2022cites this paper
• Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future

  2022cites this paper
• Immune-related adverse events in various organs caused by immune checkpoint inhibitors.

  2022cites this paper
• Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands

  2022cites this paper
• Gene Editing: a Powerful Tool for Cancer Immunotherapy

  2022cites this paper
• Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology.

  2022cites this paper
• Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy

  2022cites this paper
• The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

  2021cites this paper
• Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

  2021cites this paper
• Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

  2021cites this paper
• Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma

  2021cites this paper
• Differential involvement of programmed cell death ligands in skin immune responses.

  2021cites this paper
• The PD-1 Regulatory Axis Inhibits T Cell–Independent B Cell Memory Generation and Reactivation

  2021cites this paper
• A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy

  2021cites this paper
• A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies

  2020cites this paper
• Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus.

  2020cites this paper
• CMAR_A_257188 6493..6509

  2020cites this paper
• Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma

  2020cites this paper
• Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

  2020cites this paper
• Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges

  2020cites this paper
• Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

  2019cites this paper
• The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

  2019cites this paper
• STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth.

  2019cites this paper
• Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC

  2019cites this paper
• For Peer Review 1 PD-L 1 and PD-L 2 differ in their molecular mechanisms of interaction with PD-1

  2018cites this paper
• PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

  2018cites this paper
• Comprehensive molecular profiling of the B7 family in gastrointestinal cancer

  2018cites this paper
• Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

  2018cites this paper
• Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment

  2018cites this paper
• Potential targeting of B7‐H4 for the treatment of cancer

  2017cites this paper
• Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response

  2017cites this paper
• Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.

  2017cites this paper
• B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb

  2017cites this paper
• PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5–Dependent Mechanism

  2017cites this paper
• Recent advances in cancer immunology and immunology-based anticancer therapies.

  2017cites this paper
• Immunomodulation and Vaccination with RHDV VLP

  2017cites this paper
• This information is current as Dependent Mechanism − through an IL-5 Production against Phosphorylcholine PD-L 2 Regulates B-1 Cell Antibody

  2017cites this paper
• from Cell Death B-Dependent Protection of Dendritic Cells κ B7-DC/PD-L2 Cross-Linking Induces NF-

  2017cites this paper
• Immune checkpoint blockade in infectious diseases

  2017cites this paper
• Mesenchymal Stromal Cell Secretion of Programmed Death‐1 Ligands Regulates T Cell Mediated Immunosuppression

  2016cites this paper
• Targeting immune checkpoints in malignant glioma

  2016cites this paper
• Pembrolizumab (Keytruda)

  2016cites this paper
• PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

  2016cites this paper
• Etude pilote de l'évaluation multi-composante de l'expression tumorale et micro-environnementale de PD-L1 en tant que facteur prédictif de réponse dans les mélanomes traités par inhibiteurs de PD-1

  2016cites this paper
• Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes

  2016cites this paper
• This information is current as Intrinsic Mechanism − through a B Cell Streptococcus pneumoniae PD-1 Suppresses Protective Immunity to

  2015cites this paper
• PD-1 Suppresses Protective Immunity to Streptococcus pneumoniae through a B Cell–Intrinsic Mechanism

  2015cites this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cites this paper
• Non-allergenic factors from pollen modulate T helper cell instructing notch ligands on dendritic cells

  2015cites this paper
• Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury

  2015influential citation
• Endogenous VSIG4 negatively regulates the helper T cell-mediated antibody response.

  2015cites this paper
• Immune checkpoint inhibition in lymphoid disease

  2015cites this paper
• FOXP3 and CTLA-4 : how isoforms regulate immunological tolerance

  2015cites this paper
• CD28 costimulation in T cells : requirements, outcomes and regulation

  2014cites this paper
• Fusion Protein of Mutant B7-DC and Fc Enhances the Antitumor Immune Effect of GM-CSF-secreting Whole-cell Vaccine

  2014cites this paper
• Vaccination with Leishmania mexicana LPG induces PD-1 in CD8⁺ and PD-L2 in macrophages thereby suppressing the immune response: a model to assess vaccine efficacy.

  2014cites this paper
• Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

  2014cites this paper
• Die Lokalisation von PD-1 während des "Kiss of Death"

  2014cites this paper
• Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

  2014cites this paper
• Investigating the role of PD-L1 pathway in human ovarian cancer

  2014cites this paper
• A low, non-toxic dose of paclitaxel can prevent dendritic cell-precursors from becoming tolerogenic dendritic cells with impaired functions.

  2014cites this paper
• Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke

  2014cites this paper
• Expression of B7-H3, a Potential Factor of Tumor Immune Evasion in Combination with the Number of Regulatory T Cells, Affects Against Recurrence-Free Survival in Breast Cancer Patients

  2014cites this paper
• Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

  2013cites this paper
• At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy

  2013cites this paper
• T Cells and Costimulation in Cancer

  2013cites this paper
• Novel antibodies targeting immune regulatory checkpoints for cancer therapy

  2013cites this paper
• Expression of B7-H3 in Healthy and Diseased Gingival Samples: An Immunohistochemical Study.

  2013cites this paper
• Structure and Interactions of the Human Programmed Cell Death 1 Receptor*

  2013cites this paper
• Emerging Co-signaling Networks in T Cell Immune Regulation

  2013cites this paper
• Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches

  2013cites this paper
• The Promise of PD-1 Signaling Pathway for Cancer Immunotherapy

  2012cites this paper
• NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

  2012cites this paper
• Immunotherapy earns its spot in the ranks of cancer therapy

  2012cites this paper
• Aging‐associated B7‐DC+ B cells enhance anti‐tumor immunity via Th1 and Th17 induction

  2012cites this paper
• PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production

  2012cites this paper
• Adoptive Transfer of Immunomodulatory M2 Macrophages Prevents Type 1 Diabetes in NOD Mice

  2012cites this paper
• Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

  2012cites this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cites this paper
• Protective role of V‐set and immunoglobulin domain‐containing 4 expressed on kupffer cells during immune‐mediated liver injury by inducing tolerance of liver T‐ and natural killer T‐cells

  2012cites this paper
• Antibodies Against B7-DC with Differential Binding Properties Exert Opposite Effects

  2012cites this paper
• Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.

  2012cites this paper
• The expression, function, and clinical relevance of B7 family members in cancer

  2012cites this paper
• PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.

  2012cites this paper
• T-cell activation and transplantation tolerance.

  2012cites this paper
• Targeting the B7 Family of Co-Stimulatory Molecules

  2012cites this paper
• Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation

  2012cites this paper
• Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach

  2012cites this paper
• B 7-H 3 is a potent inhibitor of human T cell activation : No evidence for B 7-H 3 and TREML 2 interaction

  2012cites this paper
• Estudio del rol de la vía de PD-1 sobre la respuesta inmune de células Nk y de los mecanismos inmunológicos inducidos por las células Th9 frente a la infección por M. tuberculosis

  2012cites this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cites this paper
• Immunotherapy earns its spot in the ranks of cancer therapy

  2012cites this paper
• The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells.

  2011cites this paper
• Essential role of B7-H1 in double-stranded RNA-induced augmentation of an asthma phenotype in mice.

  2011cites this paper
• Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.

  2011influential citation
• Involvement of ERK and JNK pathways in IFN-γ-induced B7-DC expression on tumor cells

  2011cites this paper
• CP-CML and Not BC-CML GVL Resistant Programmed Death Ligands Render Mechanisms of T Cell Killing, but Myelogenous Leukemia (CP-CML): Shared (BC-CML) and Chronic-Phase Chronic Blast-Crisis Chronic Myelogenous Leukemia Graft-versus-Leukemia (GVL) against Mouse

  2011cites this paper